A recent "Hands On" article in Urology Times ("Post-prostate biopsy infection: Incidence and preventive steps," July 2011, pages 40-41) included a Figure that contained an error.
A recent "Hands On" article in Urology Times ("Post-prostate biopsy infection: Incidence and preventive steps," July 2011, pages 40-41) included a Figure that contained an error.
The Figure inadvertently transposed the terms "Fluoroquinolone-resistant" and "Fluoroquinolone-sensitive."
For the complete article, which includes the corrected Figure, please see urologytimes.com/HandsOnbiopsyinfection.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.